Synthesis of S-alkylated oxadiazole bearing imidazo[2,1-b]thiazole derivatives targeting breast cancer: In vitro cytotoxic evaluation and in vivo radioactive tracing studies

• Published in: Bioorganic chemistry Vol. 153; p. 107935
• Main Authors: Mohammed, Eman R., Abdel Fattah Ezzat, Manal, Seif, Emad M., Essa, Basma M., Abdel-Aziz, Hatem A., Sakr, Tamer M., Ibrahim, Hany S.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-12-2024
• Subjects: Breast cancer; Epidermal growth factor receptor; Imidazothiazole; In vivo radio tracing; Oxadiazole; Oxadiazole; Imidazothiazole; Breast cancer; In vivo radio tracing; Epidermal growth factor receptor
• ISSN: 0045-2068
• DOI: 10.1016/j.bioorg.2024.107935

[Display omitted]
•Two series of oxadiazole bearing imidazo[2,1-b]thiazole derivatives were synthesized and screened by NCI.•IC50 values for the compounds 3b, 3c, 3d and 3e which elicited remarkable GI% against three breast cancer cell lines were evaluated.•In vitro EGFR enzyme assay was performed for all compounds. Cell cycle analysis and molecular modeling were conducted for compounds 3b and 3d.•Derivative 3d was subjected to in vivo radioactive studies.
Breast cancer is the most common invasive cancer diagnosed in women, accounting for most cancer-related fatalities globally. Numerous investigations have revealed that breast cancer is characterized by abnormal expression and maintenance of EGFR levels. In terms of structural study and optimization of several EGFR inhibitors, two series of oxadiazole bearing imidazo[2,1-b]thiazole derivatives were designed and synthesized as potential EGFR inhibitors and assessed for their antitumor activity at NCI-USA. Four derivatives 3b, 3c, 3d and 3e elicited remarkable GI% against MDA-MB-468, T-47D and MCF-7 breast cancer cell lines. Thereafter, MTT assay was performed to reveal that compounds 3b (IC50 = 2.27 µM) and 3d (IC50 = 1.46 µM) showed promising cytotoxic activity against MCF-7 and MDA-MB-468 cell lines, respectively, compared to their reference drugs. Compounds 3b, 3d and 3e revealed good selectivity toward tumor cells with reasonable safety profile when tested against the normal cell line MCF-10a. In vitro EGFR inhibitory assay demonstrated that compounds 3b (IC50 = 0.099 µM) and 3d (IC50 = 0.086 µM) exhibited comparable inhibitory activity to the standard drug erlotinib (IC50 = 0.046 µM). A flow cytometric analysis demonstrated that derivatives 3b and 3d arrested the cell cycle at the S phase in MCF-7 and MDB-MB-468, respectively. Furthermore, the most active derivative 3d was subjected to in vivo radioactive studies. In-vivo biodistribution of 99mTc-3d complex showed a notable elevated accumulation in the targeted sarcoma muscle, indicating the targeting capacity of compound 3d in the tumor of sarcoma mice model. The binding mode of compounds 3b and 3d with EGFR was studied by molecular docking and was further inspected by molecular dynamic simulations. Both compounds were shown to be stable during the course of simulation and demonstrated a plausible interaction pattern with the EGFR binding pocket.